Markedsdata leveret af TwelveData og Morningstar
Nicox SA is an ophthalmology company focused on developing and commercializing treatments that support vision care and ocular health. The company’s portfolio spans prescription therapies, diagnostic tools, and eye-care products designed for conditions such as glaucoma, allergic conjunctivitis, and dry eye disease. Its current business combines proprietary research programs with licensed products, allowing it to serve eye-care practitioners and patients across international markets. Nicox SA also works on nitric oxide-based ophthalmic solutions, an area that supports its broader strategy of addressing unmet needs in eye disease management. Headquartered in Biot, France, Nicox SA plays a specialized role in the global ophthalmology market through a mix of development-stage assets and marketed products.
Baseret på 1 analytiker